ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)	9 Months Ended
	Sep. 30, 2012	Nov. 07, 2012	Sep. 05, 2012	Jun. 30, 2012
ORGANIZATION AND DESCRIPTION OF BUSINESS [Abstract]
Number of patients enrolled for open-label phase IIIb trial by Auxilium				60
Number of sites throughout U.S. and Australia at which patients were enrolled for open-label phase IIIb trial				8
Number of oral presentations	2
Number of clinical trials	2
Days within which a response from FDA is expected		60 days
FDA's goal for completing the Priority Review		6 months
Post-approval use in the U.S. of XIAFLEX prior to safety update			30 months
Number of injections administered by Auxillium	27,000
Number of injections administered to patients by Auxillium	21,000